Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802
Self-citationUpstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“However, mTOR inhibitors (temsirolimus [34], everolimus [35]) have come to represent agents of choice for mRCC.”
BackgroundSelf-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496 · cited 1×
“B7-H1 B7-H1 is a cell-surface glycoprotein within the B7 family of Tcell costimulatory molecules [179].”
BackgroundEscudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Anderson, R. G. W. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.199 · Cited by 1,942
Wild-type p53 is a cell cycle checkpoint determinant following irradiation.
Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., & Kastan, M. B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.16.7491 · Cited by 1,837
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576
Growing roles for the mTOR pathway
Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.09.009 · Cited by 1,560
Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase
Kjeldsen, L., Johnsen, A. H., Sengeløv, H., & Borregaard, N. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)82217-7 · Cited by 1,284
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Staehler, M., Negrier, S., Chevreau, C., Desai, A. A., Rolland, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.5511 · Cited by 1,085
Self-citationEnhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR
Neshat, M. S., Mellinghoff, I. K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J. J., Wu, H., & Sawyers, C. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171076798 · Cited by 969
Mori, K., Lee, H. T., Rapoport, D., Drexler, I. R., Foster, K., Yang, J., Schmidt-Ott, K. M., Chen, X., Li, J. Y., Weiss, S., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23056 · Cited by 954 · cited 1×
“NGAL has a protective effect against acute ischemic injury [156] and is high in several human cancers [157].”
BackgroundSurvivin, versatile modulation of cell division and apoptosis in cancer
Altieri, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1207113 · Cited by 900
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
p53: oncogene or anti-oncogene?
Lane, D. P., & Benchimol, S. (1990) · Genes & Development · doi:10.1101/gad.4.1.1 · Cited by 795
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.132 · Cited by 793
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Nakano, O., Sato, M., Naito, Y., Suzuki, K., Orikasa, S., Aizawa, M., Suzuki, Y., Shintaku, I., Nagura, H., & Ohtani, H. (2001) · PubMed · Cited by 774
Blank, C., Brown, I., Peterson, A. C., Spiotto, M., Iwai, Y., Honjo, T., & Gajewski, T. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3259 · Cited by 772 · cited 1×
“B7-H1 expression inhibits tumour-specific T-cell-mediated immunity through induction of T-cell apoptosis, impairs cytokine production, and diminishes the cytotoxicity of activated T cells [172,180– 182].”
BackgroundA POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA
KATTAN, M. W., REUTER, V., MOTZER, R. J., KATZ, J., & RUSSO, P. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66077-6 · Cited by 754
Beyer, M., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2006-02-002774 · Cited by 732
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., Gitlitz, B. J., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1649 · Cited by 729
Self-citationZisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.111 · Cited by 675
Self-citationBUI, M. H. T., Seligson, D. B., Han, K. R., Pantuck, A. J., Dorey, F. J., Huang, Y., Horvath, S., Leibovich, B. C., Chopra, S., Liao, S. Y., et al. (2003) · PubMed · Cited by 654
Self-citationMekhail, T. M., Abou-Jawde, R. M., BouMerhi, G., Malhi, S., Wood, L., Elson, P., & Bukowski, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.179 · Cited by 559
Erratum: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm0902-1039c · Cited by 544
Multi-Institutional Validation of a New Renal Cancer–Specific Survival Nomogram
Karakiewicz, P. I., Briganti, A., Chun, F. K.-H., Trinh, Q.-D., Perrotte, P., Ficarra, V., Cindolo, L., De La Taille, A., Tostain, J., Mulders, P. F. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1218 · Cited by 536
Self-citationCurran, S., & Murray, G. I. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00156-8 · Cited by 531
Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., & Linehan, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10589 · Cited by 531
SORBELLINI, M., KATTAN, M. W., SNYDER, M. E., REUTER, V., MOTZER, R., GOETZL, M., McKIERNAN, J., & RUSSO, P. (2005) · Journal of Urology · doi:10.1097/01.ju.0000148261.19532.2c · Cited by 528
Jensen, H. K., Donskov, F., Marcussen, N., Nordsmark, M., Lundbeck, F., & von der Maase, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9498 · Cited by 461
Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer
Atkins, M. B., Regan, M. M., McDermott, D. F., Mier, J. W., Stanbridge, E. J., Youmans, A. J., Febbo, P. G., Upton, M. P., Lechpammer, M., & Signoretti, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2019 · Cited by 402
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393
Moch, H., Schraml, P., Bubendorf, L., Mirlacher, M., Kononen, J., Gasser, T., Mihatsch, M. J., Kallioniemi, O. P., & Sauter, G. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65349-7 · Cited by 391
Wintterle, Schreiner, Mitsdoerffer, Schneider, Chen, Meyermann, Weller, M., & Wiendl (2003) · 中国神经肿瘤杂志 · Cited by 366
Use of Antibodies to RCC and CD10 in the Differential Diagnosis of Renal Neoplasms
Avery, A. K., Beckstead, J., Renshaw, A. A., & Corless, C. L. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200002000-00006 · Cited by 360
Wiesener, M. S., Münchenhagen, P., Berger, I., Morgan, N. V., Roigas, J., Schwiertz, A., Jürgensen, J. S., Gruber, G., Maxwell, P. H., Löning, S. A., et al. (2001) · PubMed · Cited by 354
Pantuck, A. J., Seligson, D. B., Klatte, T., Yu, H., Leppert, J. T., Moore, L., O'Toole, T., Gibbons, J., Belldegrun, A. S., & Figlin, R. A. (2007) · Cancer · doi:10.1002/cncr.22677 · Cited by 350
Self-citationNégrier, S., Escudier, B., Gomez, F., Douillard, J.-Y., Ravaud, A., Chevreau, C., Buclon, M., Pérol, D., & Lasset, C. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf257 · Cited by 343
Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.
Elson, P. J., Witte, R. S., & Trump, D. L. (1988) · PubMed · Cited by 340
p53, p21, pRB, and p16 Expression Predict Clinical Outcome in Cystectomy With Bladder Cancer
Shariat, S. F., Tokunaga, H., Zhou, J., Kim, J., Ayala, G. E., Benedict, W. F., & Lerner, S. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.118 · Cited by 327
Self-citationDePrimo, S. E., Bello, C. L., Smeraglia, J., Baum, C. M., Spinella, D., Rini, B. I., Michaelson, M. D., & Motzer, R. J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-32 · Cited by 318
Expression Profiling of Renal Epithelial Neoplasms
Young, A. N., Amin, M. B., Moreno, C. S., Lim, S. D., Cohen, C., Petros, J. A., Marshall, F. F., & Neish, A. S. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64120-x · Cited by 311
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
Donskov, F., & von der Maase, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9594 · Cited by 299
Akt Signaling and Cancer: Surviving but not Moving On
Toker, A., & Yoeli-Lerner, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0743 · Cited by 295
Kutikov, A., Egleston, B. L., Wong, Y.-N., & Uzzo, R. G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.4816 · Cited by 292
Swinson, D. E. B., Jones, J. L., Richardson, D., Wykoff, C., Turley, H., Pastorek, J., Taub, N., Harris, A. L., & O’Byrne, K. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.132 · Cited by 287
Kallakury, B., Karikehalli, S., Haholu, A., Sheehan, C. E., Azumi, N., & Ross, J. S. (2001) · PubMed · Cited by 280
Hollingsworth, J. M., Miller, D. C., Daignault, S., & Hollenbeck, B. K. (2007) · Cancer · doi:10.1002/cncr.22600 · Cited by 275
Yao, M. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.20.1569 · Cited by 249
Jiang, Z., Chu, P. G., Woda, B. A., Rock, K. L., Liu, Q., Hsieh, C.-C., Li, C., Chen, W., Duan, H. O., McDougal, S., et al. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70732-x · Cited by 242
Metastatic renal carcinoma comprehensive prognostic system
and DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group, Atzpodien, J., Royston, P., Wandert, T., & Reitz, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600768 · Cited by 241
Kato, K., Hida, Y., Miyamoto, M., Hashida, H., Shinohara, T., Itoh, T., Okushiba, S., Kondo, S., & Katoh, H. (2002) · Cancer · doi:10.1002/cncr.10329 · Cited by 236
Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma
Kim, H. L., Seligson, D., Liu, X., Janzen, N., Bui, M. H. T., Yu, H., Shi, T., Figlin, R. A., Horvath, S., & Belldegrun, A. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0488 · Cited by 233
Choueiri, T. K., Garcia, J. A., Elson, P., Khasawneh, M., Usman, S., Golshayan, A. R., Baz, R. C., Wood, L., Rini, B. I., & Bukowski, R. M. (2007) · Cancer · doi:10.1002/cncr.22827 · Cited by 228
Ho, C.-C., Huang, P.-H., Huang, H.-Y., Chen, Y.-H., Yang, P.-C., & Hsu, S.-M. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64442-2 · Cited by 228
Schraml, P., Struckmann, K., Hatz, F., Sonnet, S., Kully, C., Gasser, T., Sauter, G., Mihatsch, M. J., & Moch, H. (2002) · The Journal of Pathology · doi:10.1002/path.1034 · Cited by 220
LEIBOVICH, B. C., CHEVILLE, J. C., LOHSE, C. M., ZINCKE, H., FRANK, I., KWON, E. D., MERCHAN, J. R., & BLUTE, M. L. (2005) · Journal of Urology · doi:10.1097/01.ju.0000177487.64651.3a · Cited by 218
Cindolo, L., Patard, J., Chiodini, P., Schips, L., Ficarra, V., Tostain, J., de La Taille, A., Altieri, V., Lobel, B., Zigeuner, R. E., et al. (2005) · Cancer · doi:10.1002/cncr.21331 · Cited by 218
Self-citationUSING TUMOR MARKERS TO PREDICT THE SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
KIM, H. L., SELIGSON, D., LIU, X., JANZEN, N., BUI, M. H. T., YU, H., SHI, T., BELLDEGRUN, A. S., HORVATH, S., & FIGLIN, R. A. (2005) · Journal of Urology · doi:10.1097/01.ju.0000154351.37249.f0 · Cited by 216
Li, L., Yang, G., Ebara, S., Satoh, T., Nasu, Y., Timme, T. L., Ren, C., Wang, J., Tahir, S. A., & Thompson, T. C. (2001) · PubMed · Cited by 213
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
Motzer, R. J., Bukowski, R. M., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Kim, S. T., Baum, C. M., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23776 · Cited by 211
Tanaka, C., O’Reilly, T., Kovarik, J. M., Shand, N., Hazell, K., Judson, I., Raymond, E., Zumstein-Mecker, S., Stephan, C., Boulay, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1127 · Cited by 211
Choueiri, T. K., Vaziri, S. A. J., Jaeger, E., Elson, P., Wood, L., Bhalla, I. P., Small, E. J., Weinberg, V., Sein, N., Simko, J., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.05.015 · Cited by 202
Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma
Siddiqui, S. A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S. M., Krambeck, A. E., Sengupta, S., Dong, H., Cheville, J. C., Lohse, C. M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2139 · Cited by 202
BUI, M. H. T., VISAPAA, H., SELIGSON, D., KIM, H., HAN, K.-R., HUANG, Y., HORVATH, S., STANBRIDGE, E. J., PALOTIE, A., FIGLIN, R. A., et al. (2004) · Journal of Urology · doi:10.1097/01.ju.0000116444.08690.e2 · Cited by 197
Leibovich, B. C., Sheinin, Y., Lohse, C. M., Thompson, R. H., Cheville, J. C., Zavada, J., & Kwon, E. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1087 · Cited by 196
NA, X. I., WU, G., RYAN, C. K., SCHOEN, S. R., di’SANTAGNESE, P. A., & MESSING, E. M. (2003) · Journal of Urology · doi:10.1097/01.ju.0000074870.54671.98 · Cited by 194
Patard, J., Fergelot, P., Karakiewicz, P. I., Klatte, T., Trinh, Q., Rioux‐Leclercq, N., Said, J. W., Belldegrun, A. S., & Pantuck, A. J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23496 · Cited by 191
Self-citationNeutrophil gelatinase-associated lipocalin as a survival factor
Tong, Z., Wu, X., Ovcharenko, D., Zhu, J., Chen, C.-S., & Kehrer, J. P. (2005) · Biochemical Journal · doi:10.1042/bj20051020 · Cited by 187
Hypoxia-Inducible Factor 1α in Clear Cell Renal Cell Carcinoma
Klatte, T., Seligson, D. B., Riggs, S. B., Leppert, J. T., Berkman, M. K., Kleid, M. D., Yu, H., Kabbinavar, F. F., Pantuck, A. J., & Belldegrun, A. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0411 · Cited by 181
Self-citationDudderidge, T. J., Stoeber, K., Loddo, M., Atkinson, G., Fanshawe, T., Griffiths, D. F., & Williams, G. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1776 · Cited by 180
Cho, D., Signoretti, S., Dabora, S., Regan, M., Seeley, A., Mariotti, M., Youmans, A., Polivy, A., Mandato, L., McDermott, D., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.020 · Cited by 178
Negrier, S., Perol, D., Menetrier-Caux, C., Escudier, B., Pallardy, M., Ravaud, A., Douillard, J.-Y., Chevreau, C., Lasset, C., & Blay, J.-Y. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.121 · Cited by 176
Costimulatory molecule B7‐H1 in primary and metastatic clear cell renal cell carcinoma
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Chen, L., Zincke, H., Blute, M. L., Leibovich, B. C., et al. (2005) · Cancer · doi:10.1002/cncr.21470 · Cited by 174
Klatte, T., Seligson, D. B., LaRochelle, J., Shuch, B., Said, J. W., Riggs, S. B., Zomorodian, N., Kabbinavar, F. F., Pantuck, A. J., & Belldegrun, A. S. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0786 · Cited by 174
Self-citationLam, J. S., Shvarts, O., Said, J. W., Pantuck, A. J., Seligson, D. B., Aldridge, M. E., Bui, M. H. T., Liu, X., Horvath, S., Figlin, R. A., et al. (2005) · Cancer · doi:10.1002/cncr.21127 · Cited by 173
Self-citationExpression of vascular endothelial growth factor protein in human renal cell carcinoma
Jacobsen, J., Grankvist, K., Rasmuson, T., Bergh, A., Landberg, G., & Ljungberg, B. (2004) · BJU International · doi:10.1111/j.1464-410x.2004.04605.x · Cited by 173
SHARIAT, S. F., ZIPPE, C., LÜDECKE, G., BOMAN, H., SANCHEZ-CARBAYO, M., CASELLA, R., MIAN, C., FRIEDRICH, M. G., EISSA, S., AKAZA, H., et al. (2005) · Journal of Urology · doi:10.1097/01.ju.0000154696.48217.75 · Cited by 171
Self-citationMargulis, V., Lotan, Y., Karakiewicz, P. I., Fradet, Y., Ashfaq, R., Capitanio, U., Montorsi, F., Bastian, P. J., Nielsen, M. E., Muller, S. C., et al. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn451 · Cited by 167
Self-citationLiu, L., Qian, J., Singh, H., Meiers, I., Zhou, X., & Bostwick, D. G. (2007) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2007-131-1290-iaocrc · Cited by 164
Karakiewicz, P. I., Hutterer, G. C., Trinh, Q., Jeldres, C., Perrotte, P., Gallina, A., Tostain, J., & Patard, J. (2007) · Cancer · doi:10.1002/cncr.22896 · Cited by 163
Self-citationBromwich, E. J., McArdle, P. A., Canna, K., McMillan, D. C., McNicol, A.-M., Brown, M., & Aitchison, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601400 · Cited by 162
Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma
Symbas, N. P., Townsend, M. F., El-Galley, R., Keane, T. E., Graham, S. D., & Petros, J. A. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00792.x · Cited by 154
A Preoperative Prognostic Model for Patients Treated with Nephrectomy for Renal Cell Carcinoma
Karakiewicz, P. I., Suardi, N. R., Capitanio, U., Jeldres, C., Ficarra, V., Cindolo, L., TAILLE, A. D. L., Tostain, J., Mulders, P., Bensalah, K., et al. (2008) · European Urology · doi:10.1016/j.eururo.2008.07.037 · Cited by 149
Self-citationLoss of tumor suppressor protein PTEN during renal carcinogenesis
Brenner, W., Färber, G., Herget, T., Lehr, H., Hengstler, J. G., & Thüroff, J. W. (2002) · International Journal of Cancer · doi:10.1002/ijc.10303 · Cited by 147
Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma
Suzuoki, M., Miyamoto, M., Kato, K., Hiraoka, K., Oshikiri, T., Nakakubo, Y., Fukunaga, A., Shichinohe, T., Shinohara, T., Itoh, T., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600619 · Cited by 142
Lidgren, A., Hedberg, Y., Grankvist, K., Rasmuson, T., Vasko, J., & Ljungberg, B. (2005) · PubMed · Cited by 139
Caveolin‐1 overexpression is associated with aggressive prostate cancer recurrence
Karam, J. A., Lotan, Y., Roehrborn, C. G., Ashfaq, R., Karakiewicz, P. I., & Shariat, S. F. (2007) · The Prostate · doi:10.1002/pros.20557 · Cited by 135
Self-citationHoffmann, N. E., Sheinin, Y. M., Lohse, C. M., Parker, A. S., Leibovich, B. C., Jiang, Z., & Kwon, E. D. (2008) · Cancer · doi:10.1002/cncr.23296 · Cited by 129
Parker, A. S., Leibovich, B. C., Lohse, C. M., Sheinin, Y. M., Kuntz, S. M., Eckel‐Passow, J. E., Blute, M. L., & Kwon, E. D. (2009) · Cancer · doi:10.1002/cncr.24263 · Cited by 128
Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer
Raj, G. V., Thompson, R. H., Leibovich, B. C., Blute, M. L., Russo, P., & Kattan, M. W. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.01.101 · Cited by 126
Expression of vascular endothelial growth factor in renal cell carcinomas
Paradis, V., Lagha, N. B., ZEIMOURA, L., Blanchet, P., Eschwège, P., Ba, N., Benoît, G., Jardin, A., & Bédossa, P. (2000) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050458 · Cited by 125
Driessen, A., Landuyt, W., Pastorekova, S., Moons, J., Goethals, L., Haustermans, K., Nafteux, P., Penninckx, F., Geboes, K., Lerut, T., et al. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000201452.09591.f3 · Cited by 124
Rini, B. I., Jaeger, E., Weinberg, V. E., Sein, N., Chew, K., Fong, K., Simko, J., Small, E. J., & Waldman, F. M. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06376.x · Cited by 119
Shariat, S. F., Anwuri, V. A., Lamb, D. J., Shah, N., Wheeler, T. M., & Slawin, K. M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.142 · Cited by 117
Self-citationLidgren, A., Hedberg, Y., Grankvist, K., Rasmuson, T., Vasko, J., & Ljungberg, B. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.1129.11.3 · Cited by 117
Krambeck, A. E., Dong, H., Thompson, R. H., Kuntz, S. M., Lohse, C. M., Leibovich, B. C., Blute, M. L., Sebo, T. J., Cheville, J. C., Parker, A. S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2129 · Cited by 114
Zigeuner, R. E., Ratschek, M., Rehak, P., Schips, L., & Langner, C. (2004) · Urology · doi:10.1016/j.urology.2003.11.011 · Cited by 113
Self-citationSoluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients
Závada, J., Závadová, Z., Zaťovičová, M., Hyršl, L., & Kawaciuk, I. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601264 · Cited by 113
Caveolin-1 expression is associated with high-grade bladder cancer
Rajjayabun, P. H., Garg, S., Durkan, G. C., Charlton, R., Robinson, M., & Mellon, J. K. (2001) · Urology · doi:10.1016/s0090-4295(01)01337-1 · Cited by 111
den Hove, L. E. V., Gool, S. W. V., Poppel, H. V., Baert, L. V., Coorevits, L., Damme, B. V., & Ceuppens, J. L. (1997) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1997.4771375.x · Cited by 107
Porta, C., Paglino, C., AMICI, M. D., Quaglini, S., Sacchi, L., Imarisio, I., & Canipari, C. (2010) · Kidney International · doi:10.1038/ki.2009.552 · Cited by 100
Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma
Suppiah, R., Shaheen, P. E., Elson, P. J., MISBAH, S., Wood, L. S., Motzer, R. J., Négrier, S., Andresen, S. W., & Bukowski, R. M. (2006) · Cancer · doi:10.1002/cncr.22237 · Cited by 98
Parker, A. S., Kosari, F., Lohse, C. M., Thompson, R. H., Kwon, E. D., Murphy, L., Riehle, D., Blute, M. L., Leibovich, B. C., Vasmatzis, G., et al. (2006) · Cancer · doi:10.1002/cncr.21952 · Cited by 97
Li, J. F., Chu, Y. W., Wang, G. M., Zhu, T. Y., Rong, R. M., Hou, J., & Xu, M. (2009) · BJU International · doi:10.1111/j.1464-410x.2008.08151.x · Cited by 96
Carbonic Anhydrase IX as a Marker for Poor Prognosis in Soft Tissue Sarcoma
Måseide, K., Kandel, R. A., Bell, R. S., Catton, C., O’Sullivan, B., Wunder, J. S., Pintilie, M., Hedley, D. W., & Hill, R. P. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0541 · Cited by 92
Tollefson, M. K., Thompson, R. H., Sheinin, Y. M., Lohse, C. M., Cheville, J. C., Leibovich, B. C., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22840 · Cited by 89
Hutson, T. E., Davis, I. D., Machiels, J. H., de Souza, P. L., Baker-Neblett, K. L., Bordogna, W., WESTLUND, R. E., Crofts, T., Pandite, L. N., & Figlin, R. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5046 · Cited by 87
Yıldız, E., Gökçe, G., Kılıçarslan, H., Ayan, S., Göze, Ö. F., & Gültekin, E. Y. (2004) · British Journal of Urology · doi:10.1111/j.1464-410x.2004.04786.x · Cited by 86
Scott, C., Nelson, J. S., Farnan, N. C., Curran, W. J., Murray, K. J., Fischbach, A. J., Gaspar, L. E., & Nelson, D. F. (1995) · Cancer · doi:10.1002/1097-0142(19950715)76:2<296::aid-cncr2820760221>3.0.co;2-l · Cited by 84
Johnson, T., Abbasi, A., Owen‐Smith, A. A., Young, A. N., Ogan, K., Pattaras, J. G., Nieh, P. T., Marshall, F. F., & Master, V. A. (2009) · The Journal of Urology · doi:10.1016/j.juro.2009.10.014 · Cited by 83
Jiang, Z., Chu, P. G., Woda, B. A., Liu, Q., Balaji, K. C., Rock, K. L., & Wu, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0504 · Cited by 79
Hypoxia-Inducible Factor 1α Expression in Renal Cell Carcinoma Analyzed by Tissue Microarray
Lidgren, A., Hedberg, Y., Grankvist, K., Rasmuson, T., Bergh, A. R. J., & Ljungberg, B. (2006) · European Urology · doi:10.1016/j.eururo.2006.05.043 · Cited by 78
Shariat, S. F., Karakiewicz, P. I., Godoy, G., Karam, J. A., Ashfaq, R., Fradet, Y., Isbarn, H., Montorsi, F., Jeldres, C., Bastian, P. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2554 · Cited by 78
Self-citationCózar, J. M., Cantón, J., Tallada, M., Concha, Á., Cabrera, T., Garrido, F., & Ruiz‐Cabello, F. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0646-1 · Cited by 76
Donskov, F., Hokland, M., Marcussen, N., Torp Madsen, H. H., & von der Maase, H. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602937 · Cited by 73
Rasmuson, T., Grankvist, K., Jacobsen, J., Olsson, T., & Ljungberg, B. (2004) · Acta Oncologica · doi:10.1080/02841860410017260 · Cited by 67
Escudier, B. J., Choueiri, T. K., Oudard, S. M., Szczylik, C. A., Négrier, S., Ravaud, A., Chevreau, C., Venner, P. M., Champagne, P., Croteau, D., et al. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.07.035 · Cited by 62
Self-citationCampbell, L., Jasani, B., Edwards, K., Gumbleton, M., & Griffiths, D. F. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604243 · Cited by 57
Rioux-Leclercq, N. C., Fergelot, P., Zerrouki, S., Leray, E., Jouan, F., Bellaud, P., Epstein, J. I., & Patard, J. (2007) · Human Pathology · doi:10.1016/j.humpath.2007.02.014 · Cited by 57
Flow cytometric analysis of tumour‐infiltrating lymphocytes in patients with renal cell carcinoma
Kowalczyk, D. W., Skorupski, W., Kwias, Z., & Nowak, J. (1997) · British Journal of Urology · doi:10.1046/j.1464-410x.1997.00408.x · Cited by 56
p53 Mutations and Other Prognostic Factors of Renal Cell Carcinoma
Girgin, C., Tarhan, H., Hekimgil, M., SEZER, A., & Gürel, G. (2001) · Urologia Internationalis · doi:10.1159/000056575 · Cited by 56
Kitamura, H., Honma, I., Torigoe, T., Asanuma, H., Sato, N., & Tsukamoto, T. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.11.082 · Cited by 54
Négrier, S., Gomez, F., Douillard, J., Ravaud, A., Chevreau, C., Buclon, M., Pérol, D., Lasset, C., & Escudier, B. J. (2005) · World Journal of Urology · doi:10.1007/s00345-004-0467-z · Cited by 53
Kolbeck, P. C., Kaveggia, F. F., Johansson, S. L., Grune, M. T., & Taylor, R. J. (1992) · PubMed · Cited by 50
Cindolo, L., Chiodini, P., Gallo, C., Ficarra, V., Schips, L., Tostain, J., TAILLE, A. D. L., Artibani, W., & Patard, J. (2008) · Cancer · doi:10.1002/cncr.23517 · Cited by 49
Self-citationSurvivin Expression in Renal Cell Carcinoma
Zamparese, R., Pannone, G., Santoro, A., Muzio, L. L., Corsi, F., Pedicillo, M. C., Scillitani, E. L., Tortorella, S., Staibano, S., Piscuoglio, S., et al. (2008) · Cancer Investigation · doi:10.1080/07357900802017553 · Cited by 43
Zigeuner, R. E., Droschl, N., Tauber, V., Rehak, P., & Langner, C. (2006) · Urology · doi:10.1016/j.urology.2006.03.032 · Cited by 42
Self-citationDorai, T., Sawczuk, I. S., Pastorek, J., Wiernik, P. H., & Dutcher, J. P. (2006) · Cancer Investigation · doi:10.1080/07357900601062321 · Cited by 36
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma
Williams, A., Higgins, J., Zhao, H.-J., Ljunberg, B., & Brooks, J. (2009) · BMC Clinical Pathology · doi:10.1186/1472-6890-9-9 · Cited by 35
Choueiri, T. K., Vaziri, S. A. J., Rini, B. I., Elson, P. J., Bhalla, I. P., Jaeger, E., WEINBERG, V. K., Waldman, F., Zhou, M., Bukowski, R. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5012 · Cited by 28
Immunophenotypic markers in renal cell carcinoma.
Banner, B. F., Burnham, J. A., Bahnson, R. R., Ernstoff, M. S., & Auerbach, H. E. (1990) · PubMed · Cited by 26
Kawata, N., 長根, 裕., 五十嵐, 匠., Hirakata, H., Ichinose, T., Hachiya, T., Takimoto, Y., & Takahashi, S. (2006) · Urology · doi:10.1016/j.urology.2006.03.063 · Cited by 24
Igarashi, T., Murakami, S., Takahashi, H., Matsuzaki, O., & Shimazaki, J. (1992) · European Urology · doi:10.1159/000474780 · Cited by 21
Junker, K., von Eggeling, F., Müller, J., Steiner, T., & Schubert, J. (2006) · Der Urologe · doi:10.1007/s00120-006-1001-2 · Cited by 17
(1996) · PubMed
Cited by
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.005 · Cited by 3,394
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J. J., Khoo, V., Eisen, T., & Horwich, A. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu259 · Cited by 2,251
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Grünwald, V., Gillessen, S., & Horwich, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz056 · Cited by 1,151
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B., Porta, C., Schmidinger, M., Rioux-Leclercq, N., Bex, A., Khoo, V., Gruenvald, V., & Horwich, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw328 · Cited by 509
Pichler, M., Hutterer, G. C., Stoeckigt, C., Chromecki, T. F., Stojakovic, T., Golbeck, S., Eberhard, K., Gerger, A., Mannweiler, S., Pummer, K., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.28 · Cited by 275
Self-citation
Metadata
- Authors
- Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 60
- Issue
- 4
- Pages
- 644-661
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W1998628385
- Cited by
- 325
- References
- 144
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.